VNDA

Gunther Birznieks

Known title: SVP, Business DevelopmentCIK: 0001702031

Associated companies

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

September 26, 2026

Oppenheimer Launches Coverage on Vanda Pharmaceuticals. Oppenheimer has begun covering Vanda Pharmaceuticals, issuing an outperform rating and a $10 price target. The target sits near the middle of the analyst range and below the 52‑week high, suggesting a cautious upside view. The stock is trading above its $5.21 support level with an RSI of 41.6, indicating room for movement.

this person other insiders at VNDA

Transaction History

VNDA▼ Sell$351K
VNDA▲ Buy$0
VNDA▼ Sell$128K
VNDA▲ Buy$0
VNDA▼ Sell$36K
VNDA▼ Sell$37K
VNDA▲ Buy$0
VNDA▼ Sell$52K
VNDA▼ Sell$53K
VNDA▲ Buy$0
VNDA▲ Buy$4K
VNDA▼ Sell$130K
VNDA▼ Sell$46K
VNDA▲ Buy$0

We use analytics to understand how market-wall is used. No personal data is sold.